智通财经记者 | 黄华 智通财经编辑 | 谢欣 在诺和诺德（Novo Nordisk）宣布下调业绩增速指引，礼来公司（Eli Lilly and Company）公布产品替尔泊肽（Tirzepatide）的心血管保护作用非劣效于度拉 糖肽（Dulaglutide）之后，8月1日，博瑞医药宣布将旗下明星产品BGM0504授权给华润三九，累计的研发投入里程碑付款最高为2.8亿元。 2.8亿元让这起商业授权快速获得了关注。累计里程碑付款代表了某一款产品后续的市场空间想象力，而博瑞医药的这一数据明显低于近期国内的一系列国 产创新药商业授权（BD）金额以及国内GLP-1产品的出海记录。 8月4日，博瑞医药开盘后小幅下跌。自年初至今，博瑞医药累计涨幅超220%。同在8月4日，华润三九开盘后小幅上涨。 截至8月4日收盘，博瑞医药报98.07元/股，跌1.19%，最新市值约415亿元。华润三九报32.12元/股，涨2.07%，最新市值约536亿元。 随后，博瑞医药对于市场对此交易几大热点问题向智通财经记者予以了回应。 回应一：2.82亿元不是授权费用 GLP-1（胰高血糖素样肽 1）领域的头部产品是司美格鲁肽（Sermagl ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [31]. Core Insights - The pharmaceutical and biotechnology sector has shown strong performance, with an overall increase of 2.95% in the last week, outperforming the CSI 300 index by 4.70 percentage points. Year-to-date, the sector has risen by 22.31%, ranking second among 31 industries [3][12]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 30.88 times, which is at the historical median level, with a valuation premium of 148% compared to the CSI 300 index [17]. - Notable stock performances include Nanjing New Pharmaceutical with a 78.01% increase, followed by Lide Medical and Chenxin Pharmaceutical with increases of 46.45% and 40.88%, respectively [23][24]. Market Performance - The pharmaceutical and biotechnology sector ranked first among 31 industries last week, with a 2.95% increase, while the top three sub-sectors were chemical pharmaceuticals, traditional Chinese medicine II, and biological products, with increases of 5.01%, 3.12%, and 2.69%, respectively [11]. - Year-to-date, the top-performing sub-sectors include chemical pharmaceuticals, medical services, and biological products, with increases of 40.97%, 35.89%, and 16.54%, respectively [12]. Industry News - Heng Rui Medicine has entered into an agreement with GSK for the global exclusive rights to the PDE3/4 inhibitor HRS-9821, with an upfront payment of $500 million and potential milestone payments totaling approximately $12 billion [4][25]. - CSPC Pharmaceutical has signed an exclusive licensing agreement with Madrigal for the oral small molecule GLP-1 receptor agonist SYH2086, with a total potential value of up to $2.075 billion [4][26]. - Borui Pharmaceutical is collaborating with China Resources Sanjiu to further develop the BGM0504 injection, a dual agonist for GLP-1 and GIP receptors, which is currently in the critical phase of clinical trials [4][27]. Investment Recommendations - The report suggests that the innovative drug sector remains a core investment theme for the second half of the year, with a focus on GLP-1 dual-target new drugs and various sub-sectors such as CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [5][28]. - Recommended stocks include Betta Pharmaceuticals, Teva Biopharmaceuticals, Kaili Medical, Haier Biomedical, Huaxia Eye Hospital, and Lao Bai Xing [5][28].

本报讯(记者刘钊)《证券日报》记者从中康数字科技有限公司(以下简称"中康科技")了解到，第十八届 西普会(健康产业生态大会)即将于8月16日至8月21日在海南博鳌举行。本届西普会以"快蜕变，穿越新 周期增长元动力重构与产业生态进化"为主题，旨在探讨健康产业在新周期下的发展趋势。会议将围绕 政策深化、科技创新、市场需求等关键议题展开讨论，并发布《新周期展望》《健康产业未来格局》等 行业报告，为行业发展提供趋势预判。 西普会由中康科技主办，自2008年创办以来，已成为中国健康产业的重要交流平台。本届会议将进一步 促进产业链各环节的协同合作，助力行业应对新周期挑战。 人工智能在健康产业的应用成为本届大会的亮点之一。"AI For Health高峰论坛"将连续举办三天，围 绕"超级个体赋能"与"前沿组织进化"两大主题展开讨论。会上将分享同济医院急诊科AI指挥官应用、云 南白药（000538）AI创新研发实践、互联网产品人机交互专家利用AI零代码编程助力代际健康守护等 实际案例，深入探讨人工智能在医药营销、临床决策、患者管理及企业组织形态重塑等方面的应用前 景。 在产业链协同方面，大会将搭建工业、零售与资本的深度交流平 ...

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has entered into a collaborative research and development agreement with Borui Biopharmaceutical (Suzhou) Co., Ltd. for the BGM0504 injection project, which is a dual agonist of GLP-1 and GIP receptors aimed at treating Type 2 Diabetes Mellitus (T2DM) and obesity [1][2] Group 1: Collaboration Details - The BGM0504 injection is positioned as an innovative polypeptide drug that aims to provide more effective, safer, and convenient treatment options for patients [1] - The collaboration grants China Resources Sanjiu exclusive development and commercialization rights, indicating a deep complementarity in innovative drug development and commercialization capabilities between the two companies [1][2] - China Resources Sanjiu's investment covers the entire R&D and commercialization chain, with a maximum milestone payment of 282 million yuan contingent on clinical progress and regulatory approval [2][3] Group 2: Clinical Trial Progress - BGM0504 has reached the critical phase of Phase III clinical trials, with Phase II trials showing promising results in both T2DM patients and overweight/obese adults, indicating potential advantages over existing treatments like semaglutide [2][4] - The Phase II trials demonstrated significant weight management potential and metabolic risk benefits in the overweight/obese population [2] Group 3: Market Competition - The GLP-1 market is highly competitive, with major players like Novo Nordisk and Eli Lilly dominating the space, collectively generating approximately $29.3 billion in sales from various formulations of semaglutide and other GLP-1 products [5] - The competitive landscape includes over 179 GLP-1 pipelines from 45 companies globally, indicating intense competition and the challenge for BGM0504 to establish a foothold in the market [7] - Recent approvals and developments in the GLP-1 space, such as Innovent's dual receptor agonist and Eli Lilly's oral GLP-1 drug, further intensify the competition [6][7]

Core Viewpoint - The report from Guotai Haitong indicates that 2025 will be the year of commercialization for domestically developed innovative weight loss drugs with global competitiveness, following the first prescription issued for Innovent Biologics' injection of Ma Shidu peptide on July 3, marking a significant milestone in China's innovative weight loss drug development [1]. Industry Progress - Domestic innovative drug development in the weight loss sector has made substantial progress, including: - Zhongsheng Pharmaceutical completed the enrollment of all participants in the Phase III clinical trial for RAY1225 on July 31, with the first participant enrolled in June, showcasing rapid and efficient progress. The bi-weekly dosing regimen demonstrated significant advantages, with a 15.05% average weight reduction over 24 weeks in the 9mg group from Phase II study data [1]. - United BioPharma's UBT37034 received FDA IND approval, which selectively targets neuropeptide Y2 receptors to reduce weight. Preclinical studies showed that UBT37034 combined with GLP-1 analogs significantly reduced weight, outperforming other investigational drugs [1]. Company Developments - Several domestic pharmaceutical companies have made significant advancements in their weight loss drug pipelines: - LaiKai Pharmaceuticals received FDA approval for the clinical trial IND application of LAE103 on July 31, fully laying out the ActRIIA+B pathway [2]. - Gilead Sciences is expected to obtain 12-week Phase IIa data for ASC30 by Q1 2026 [2]. - Innovent Biologics' small molecule GLP-1 drug IBI3032 had its clinical trial application accepted by NMPA on July 16 [2]. - HengRui Medicine reported an average weight loss of 19.2% in the 6mg dose group during a 48-week Phase III trial, with plans to submit a new drug application soon [2]. Collaborations and Licensing - In 2023, several domestic pharmaceutical companies completed multiple licensing and collaboration deals related to weight loss drugs: - On July 30, CSPC Pharmaceutical Group licensed its oral GLP-1 small molecule SYH2086 to Madrigal Pharma for global development, production, and commercialization outside of China, with a total deal value of $2.075 billion, including a $120 million upfront payment [3]. - Borui Pharmaceutical reached a collaboration agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [3].

金融界消息 截至2025年8月4日收盘，华润三九（000999）报收于32.12元，上涨2.07%，换手率1.4%， 成交量23.25万手，成交金额7.44亿元。 天眼查商业履历信息显示，华润三九医药股份有限公司，成立于1999年，位于深圳市，是一家以从事医 药制造业为主的企业。企业注册资本128429.8685万人民币，实缴资本128429.8685万人民币。公司法定 代表人为吴文多。 通过天眼查大数据分析，华润三九医药股份有限公司共对外投资了51家企业，参与招投标项目5000次， 知识产权方面有商标信息2216条，专利信息556条，此外企业还拥有行政许可325个。 来源：金融界 资金流向方面，今日主力资金净流入8617.18万元，占比成交额11.59%。其中，超大单净流入4137.07万 元、占成交额5.56%，大单净流入4480.11万元、占成交额6.02%，中单净流出流出2933.23万元、占成交 额3.94%，小单净流出5683.95万元、占成交额7.64%。 华润三九最新一期业绩显示，截至2025一季报，公司营业总收入68.54亿元、同比减少6.04%，归属净利 润12.70亿元，同比减少6.87 ...

Core Insights - The Chinese healthcare investment market has experienced significant fluctuations over the past decade, peaking at over 380 billion yuan in 2021 before entering a period of stagnation [6][7] - Many healthcare unicorns emerged during the investment boom, but high valuations and slow conversion rates have led to persistent losses and challenges in achieving IPOs [6][10] - The industry is undergoing a transformation from a focus on high valuations and rapid growth to a more sustainable approach centered on survival and cash flow [12][17] Investment Trends - Since 2021, several companies, including Yuanxin Technology and Yingsi Intelligent, have struggled to enter the secondary market despite multiple IPO attempts [7] - The withdrawal of dollar funds and the cautious approach of domestic RMB funds have changed the funding landscape, leading to difficulties in financing and exits for many startups [7][10] - In the first half of this year, nearly 40 healthcare companies submitted IPO applications in Hong Kong, indicating a potential recovery in the market [7][9] Mergers and Acquisitions - Major acquisitions have gained attention, with companies like CR Sanjiu and Ant Group making significant purchases, suggesting a shift from IPO aspirations to M&A strategies for some unicorns [9][11] - The Hong Kong healthcare sector is showing signs of recovery, with several unicorns reapplying for IPOs after a period of dormancy [9][10] - Many companies are opting for mergers as a means to exit, although this often results in losses for investors due to previously inflated valuations [20][21] Market Dynamics - The healthcare industry is experiencing a profound reshaping, with a collective recalibration of expectations among entrepreneurs and investors [10][12] - The focus has shifted from visionary narratives to practical cash flow and profitability, with investors now prioritizing immediate financial returns over long-term potential [16][17] - Companies are adopting survival strategies, including layoffs and product line reductions, to maintain cash flow and navigate the current market challenges [11][12] Future Outlook - While IPOs remain a preferred exit strategy, not all companies are equipped to pursue this path, leading to a reliance on mergers as an alternative [19][20] - The market is expected to reward companies that can demonstrate sustainable business models and adaptability to policy changes, rather than those that merely tell compelling stories [21] - The healthcare sector is characterized by a slow evolution, requiring patience and resilience from companies as they adapt to the new market realities [21]

Group 1 - The US job market shows signs of cooling, with July non-farm payrolls increasing by only 74,000, below the expected 104,000, and revisions for May and June totaling a downward adjustment of 258,000 to 19,000 and 14,000 respectively, indicating a significant slowdown since April [1] - The overall US stock market declined, with the S&P 500, Nasdaq, and Dow Jones falling by 1.6%, 2.2%, and 1.2% respectively [1] - The non-farm report reflects a shift in the job market from stability to noticeable cooling, with interest rate cut expectations rising to 60 basis points and a 90% probability of a cut in July [1] Group 2 - Market style rotation is occurring, with funds moving from high valuation sectors to reasonably valued sectors, leading to a gradual rebound in core assets at the bottom [2] - Medical innovation sectors, including CXO (WuXi AppTec/Tigermed), medical devices (Mindray), medical consumption (Aier Eye Hospital/Aimei), and vaccines (Changchun High-tech), are highlighted as core assets that have significantly declined [2] - Many of the top ten component stocks are trading below the historical 20th percentile in terms of valuation, indicating a strong margin of safety [2] - Weak US economic and employment data may accelerate the pace of Federal Reserve interest rate cuts, enhancing global liquidity and benefiting technology stocks [2] - Investors who missed the first half of the medical sector rally can position themselves in the medical innovation ETF (516820) to capitalize on the recovery [2]

Group 1 - A total of 40 stocks received buy ratings from brokerages on August 1, with 10 stocks announcing target prices [1] - Based on the highest target prices, China Resources Sanjiu, Meihua Biological, and Ninebot Company-WD ranked highest in target price increase, with expected increases of 49.09%, 47.85%, and 38.13% respectively [1] - Among the rated stocks, 30 maintained their ratings, while 10 received ratings for the first time [1] Group 2 - Five stocks attracted attention from multiple brokerages, with Hisense Home Appliances, Oriental Yuhong, and Qingdao Bank receiving the most ratings, at 4, 3, and 3 brokerages respectively [1] - In terms of industry distribution, the highest number of buy-rated stocks belonged to Capital Goods, Durable Consumer Goods & Apparel, and Technology Hardware & Equipment, with 7, 6, and 4 stocks respectively [1]

Group 1 - President Trump has demanded major pharmaceutical companies to take measures to lower drug prices in the U.S. within 60 days, threatening to use "all means" if they refuse [1] - The announcement has led to a significant drop in stock prices of several pharmaceutical companies, indicating increased uncertainty regarding their future profitability [1] - This action reflects the U.S. government's strong intervention in drug pricing, which may pressure pharmaceutical companies to optimize costs and innovate in the long term [1] Group 2 - Genscript Biotech announced a strategic increase in its stake in I-Mab, investing $30.9 million, making it the largest shareholder with approximately 16.1% ownership [2] - This investment is expected to enhance Genscript's competitiveness in the innovative drug sector and provide I-Mab with financial support to accelerate the development of its clinical pipeline [2] - The partnership is anticipated to positively impact the stock prices of both companies [2] Group 3 - Anhui Province has initiated a centralized procurement process for monoclonal antibodies, with 8 monoclonal antibodies included in the information collection, and the highest competition seen in Bevacizumab with 13 manufacturers [3] - The centralized procurement is likely to compress profit margins for pharmaceutical companies but may also accelerate market consolidation and encourage companies to improve R&D efficiency and cost control [3] - Short-term stock prices of related pharmaceutical companies may face pressure, but long-term benefits could arise from increased industry concentration and the development of innovative drugs [3] Group 4 - Borui Pharmaceutical has signed a cooperation and research agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [4] - The agreement includes milestone payments from China Resources Sanjiu to Borui Pharmaceutical, totaling up to 282 million yuan [4] - This collaboration is expected to expedite the commercialization process of BGM0504 in China, positively impacting Borui Pharmaceutical's future operating performance [4]